Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,020
  • Shares Outstanding, K 24,727
  • Annual Sales, $ 34,260 K
  • Annual Income, $ -45,720 K
  • EBIT $ -52 M
  • EBITDA $ -50 M
  • 60-Month Beta 1.28
  • Price/Sales 4.34
  • Price/Cash Flow N/A
  • Price/Book 1.62

Options Overview Details

View History
  • Implied Volatility 780.45% (+105.67%)
  • Historical Volatility 88.04%
  • IV Percentile 87%
  • IV Rank 57.31%
  • IV High 1,350.68% on 03/11/26
  • IV Low 14.92% on 12/16/25
  • Expected Move (DTE 17) 0.26 (4.70%)
  • Put/Call Vol Ratio 5.00
  • Today's Volume 12
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 917
  • Open Int (30-Day) 1,867
  • Expected Range 5.17 to 5.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -2.21
  • Growth Rate Est. (year over year) +87.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.01 +35.10%
on 03/02/26
7.59 -28.59%
on 03/18/26
+1.22 (+29.05%)
since 02/27/26
3-Month
3.53 +53.54%
on 02/05/26
7.59 -28.59%
on 03/18/26
+1.19 (+28.13%)
since 12/26/25
52-Week
3.53 +53.54%
on 02/05/26
8.82 -38.55%
on 10/29/25
+0.72 (+15.32%)
since 03/28/25

Most Recent Stories

More News
Precision BioSciences: Q4 Earnings Snapshot

Precision BioSciences: Q4 Earnings Snapshot

DTIL : 5.42 (-9.97%)
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - ...

TGTX : 31.51 (-0.76%)
DTIL : 5.42 (-9.97%)
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies...

DTIL : 5.42 (-9.97%)
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

– Findings reinforce differentiated in vivo gene editing approach designed for durable functional muscle improvement through satellite cell editing – – PBGENE-DMD treatment...

DTIL : 5.42 (-9.97%)
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet...

DTIL : 5.42 (-9.97%)
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy – – March 17, 2026 virtual...

DTIL : 5.42 (-9.97%)
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock – – Cash received supports Precision’s expected cash runway through...

TGTX : 31.51 (-0.76%)
DTIL : 5.42 (-9.97%)
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet...

DTIL : 5.42 (-9.97%)
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – ...

DTIL : 5.42 (-9.97%)
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026 PBGENE-DMD expecting...

DTIL : 5.42 (-9.97%)

Business Summary

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.

See More

Key Turning Points

3rd Resistance Point 6.32
2nd Resistance Point 6.13
1st Resistance Point 5.78
Last Price 5.42
1st Support Level 5.24
2nd Support Level 5.05
3rd Support Level 4.70

See More

52-Week High 8.82
Fibonacci 61.8% 6.80
Fibonacci 50% 6.17
Fibonacci 38.2% 5.55
Last Price 5.42
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.